N3C IPTW retrospective 4,992 COVID-19 patients in the USA treated with sotrovimab and 541,325 controls, showing lower combined hospitalization or mortality.Confounding by treatment propensity.
This study analyzes a population
where only a fraction of eligible patients received the treatment. Patients
receiving treatment may be more likely to follow other recommendations, more
likely to receive additional care, and more likely to receive additional
treatments that are not tracked in the data (e.g., nasal/oral hygiene
c19early.org, c19early.org (B)
, vitamin D
, etc.) — either because the physician
recommending sotrovimab also recommended them, or
because the patient seeking out sotrovimab is more
likely to be familiar with the efficacy of additional treatments. Therefore,
these kind of studies may overestimate the efficacy of treatments.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.1 Liu, Sheward, VanBlargan and a lack of efficacy for BA.2 Zhou. US EUA has been revoked.
risk of death/hospitalization, 25.1% lower, RR 0.75, p = 0.004, NNT 107, odds ratio converted to relative risk, propensity score weighting, day 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bell et al., 12 Jun 2023, retrospective, USA, peer-reviewed, 11 authors, study period 26 May, 2021 - 30 April, 2022.
THE EFFECTS OF OBESITY AND METABOLIC SYNDROME ON KIDNEY TRANSPLANT OUTCOMES IN YOUNG PATIENTS: A RETROSPECTIVE STUDY
propensity score matched and adjusted linear regression. Results: Of 135,729 patients meeting our study criteria, 12,848 remained after 1:1 propensity score matching. Cardiovascular outcomes did not differ significantly between those on an SGLT2i and metformin (hazard ratio: 1.025 [95% CI: 0.901, 1.166]). Among those with baseline and 12-month A1c values available (n = 5,472), SGLT2i use was associated with a smaller absolute decrease in A1c by 0.25% (0.19% -0.32%). Conclusions: In a real-world EHR dataset, patients initiated on an SGLT2i had similar risk of cardiovascular events to those initiated on metformin, but experienced a smaller 12-month reduction in A1c.